Jubilant Ingrevia Ltd. · NSE:JUBLINGREA

Jubilant Ingrevia — Investor Presentation (September 2021)

31 slides from Jubilant Ingrevia's investor presentation, Sep 13, 2021

  1. Slide 1: Intimation of Investor/Analyst Meetings

    September 13, 2021 BSE Limited National Stock Exchange of India Limited P. J. Towers Exchange Plaza Dalal Street, Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Dear Sirs, Sub.: Intimation of Investor/ Analyst Meetings Pursuant to the provisions of Regulation 30 of the Securities

  2. Slide 2: Investor Presentation September'21

    Investor Presentation September’21

  3. Slide 3: Disclaimer

    Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f

  4. Slide 4: Jubilant Bhartia Group - Snapshot

    Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services and Therapeutics, Performance Polymers

  5. Slide 5: Jubilant Ingrevia: Glorious Four Decades of Growth

    Jubilant Ingrevia: Glorious Four Decades of Growth 2019: Started new Acetic Anhydride plant, Bharuch SEZ, GJ (50 KTA) Our Journey 10+ years experience 2018: Started Agro Intermediate plant (800 TPA), Bharuch SEZ in Vitamin B3 2017: Certified for Responsible Care (RC) Demerger into 2015: Commissioned

  6. Slide 6: Business Segments & Integrated Operations

    Business Segments & Integrated Operations Integrated Operations… Vertical integration across the value chain enables cost competitive advantage Nutrition &  For Vitamin B3 (Niacinamide & Niacin), 100% in-house sourcing of Beta Picoline Speciality Nutrition & Health Life Science Health Solutions (Ke

  7. Slide 7: Executive Leadership Team

    Executive Leadership Team Rajesh Srivastava Chief Executive Officer & Managing Director 34 years of industry experience Anil Khubchandani R Kumar Chandan Singh President – President – Nutrition & President – Speciality Chemicals Health Solutions Life Science Chemicals 29 years of industry 35 years o

  8. Slide 8: Jubilant Ingrevia: Company Snapshot

    Jubilant Ingrevia: Company Snapshot Business Segments Leadership Revenue Segmentation: By Region Total 1400+ customers - Amongst top 2 in (Pyridine + Beta Picoline) *Deemed • Speciality Chemicals: 420 Speciality Chemicals RoW Export: 15% - Globally # 1 in 11 Pyridine Derivatives • Nutrition & Health

  9. Slide 9: Strong Presence in Industry Value Chain

    Strong Presence in Industry Value Chain CDMO Services Commercial Scale Clinical Phase Manufacturing Intermediates / Discovery Process Development API Formulation Phase I / II / III Custom Manufacturing • Route Design, Process • Phase III: 4 Intermediates for Anti-Viral Jubilant Ingrevia’ s familiari

  10. Slide 10: Industry Overview: Presence in Large & Growing Markets

    Industry Overview: Presence in Large & Growing Markets Global Speciality Chemicals Global API Market Global Market: Jubilant’s Products CAGR 6.4% CAGR 5.8% CAGR $ 910 Bn $ 1240 Bn $ 197 Bn $ 262 Bn $ 1221 Mn 2.3% $ 1366 Mn Speciality FY'21 FY 26 P FY'21 FY'26 P FY'21 FY'26 P Chemicals Indian Special

  11. Slide 11: Business Segments

    lw | | JUBLIANT | INGREVIA BUSINESS SEGMENTS

  12. Slide 12: Speciality Chemicals – Segment Snapshot

    Speciality Chemicals – Segment Snapshot Amongst top 2 Region wise Revenue Segmentation (FY’21) Key Investment Projects 85 Products Globally in Globally lowest (Pyridines & Picolines, cost producer of Domestic Sales 2 Cyanopyridines, (Pyridine+Beta), - 1 Pyridine offering Japan,3% for International P

  13. Slide 13: Nutrition & Health Solutions – Segment Snapshot

    Nutrition & Health Solutions – Segment Snapshot Region-wise Revenue Segmentation (FY’21) Key Investment Projects 5 Nutrition 100% in-house Global top 2 in Domestic 1 Ingredients & sourcing of Beta Nutrition Premix 2 Vitamin B3 RoW, Sales for Facility upgrade 18+ branded Picoline (Key RM) Domestic Pl

  14. Slide 14: Life Sciences Chemicals – Segment Snapshot

    Life Sciences Chemicals – Segment Snapshot Leadership in Among top Region wise Revenue Segmentation (FY’21) Key Investment Projects 8 Products merchant market suppliers of For Segment For Acetic Anhydride 1 (Acetic Anhydride, Ethyl of Acetic Fuel grade Acetate ,Propionic Domestic Sales for Anhydride

  15. Slide 15: Multi Location Manufacturing & Operation Excellence

    Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India Nira, Maharashtra, India Samlaya, Gujarat, India Ambernath, India Speciality Chemicals, Life Science Chemicals Animal Nutrit

  16. Slide 16: Jubilant Ingrevia: Global Accreditation

    Jubilant Ingrevia: Global Accreditation Select Certifications Gajraula Bharuch Nira Samlaya Ambernath No. of plants 36 5 13 5 2 Responsible Care   RC 14001:2015 ISO      9001:2015 ISO    22000:2005 ISO     14001:2015 ISO    45001:2018 FSSAI     FAMI-QS   HALAL    KOSHER  

  17. Slide 17: Business Excellence and Digital Transformation

    Business Excellence and Digital Transformation Belt Competencies (FY’21) Digital Transformation Black Belts: 08 Green Belts: 98 Yellow Belts: 141  Our journey started in 2018 with an objective to improve Business Excellence  Operational efficiency Tools & Processes  Business & Supply chain proces

  18. Slide 18: Research Development & Technology (RDT)

    Research Development & Technology (RDT) 3 RDT centers in Noida, Gajraula and Bharuch 35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Key Grignard etc. Highlights 90 highly qualified scientists (~20 PhDs) > 65 New Products Pipeline for next 5

  19. Slide 19: CSR - Jubilant Bhartia Foundation

    CSR - Jubilant Bhartia Foundation Mission: To develop multi-stakeholder sustainable models to bring about Established ‘social change’ involving knowledge generation & sharing, experiential in 2007 learning & entrepreneurial ecosystem *A sister organization of World Economic Forum*in Partnership with

  20. Slide 20: Sustainability Journey

    Sustainability Journey 2001 2002 2003 2008 2009 2010 2012 2013 2014 2019 Climate Became Jubilant First Product Change UNGC Sustainability Sustainability Sustainability Bhartia Life Cycle 1st EvoVadis Responsible ISO 14000 Mitigation Signatory Goals created Policy Report Foundation Assessment Review

  21. Slide 21: #JubilantCares | Our Efforts during Pandemic

    #JubilantCares | Stronger Together | Our Efforts during Pandemic Oxygen Support Ambulances & RTPCR Testing during Crisis Hospital Assistance Isolation Centers Vaccination Drive Camps Provided oxygen cylinders Provided Assistance in Company aided Massive Vaccination Organized RTPCR & concentrators at

  22. Slide 22: Financials

    w JUBUANT \INGREVIA Financials

  23. Slide 23: Jubilant Ingrevia – Q1'FY22 Financial Highlights

    Jubilant Ingrevia – Q1'FY22 Financial Highlights 1 2 Particulars Q1'FY21 Q1'FY22 YoY (%) • Revenue grew by 55% on YoY basis, driven by robust growth in volume and prices. Revenue • Speciality Chemicals revenue grew by 18% YoY driven by volume growth across Speciality Chemicals 257 305 18% product se

  24. Slide 24: Debt Profile – Q1 FY22

    Debt Profile – Q1 FY22 1 Particulars 31/Mar/21 30/Jun/21 Long Term Borrowings 456 227 Short Term Borrowings 92 230 Total 548 457 Cash & Equivalent 117 70 Net Debt 431 386 QoQ change - -10%  Gross Debt reduction of Rs 91 Crore in Q1’FY 22.  Net Debt reduction of Rs 45 Crore in Q1’FY22.  Net Debt t

  25. Slide 25: FY21 Financial Highlights (Pro-forma)

    Jubilant Ingrevia Limited – FY21 Financial Highlights (Pro-forma2) 1 Particulars FY20 FY21 YoY (%) • Revenue grew by 10% on YoY basis, driven by growth in volume Revenue Speciality Chemicals 1,104 1,124 2% and pricing both. Nutrition & Health Solutions 537 630 17% • Speciality Chemicals revenue grew

  26. Slide 26: Balance Sheet – Key Parameters/Ratios (Pro-Forma)

    Balance Sheet – Key Parameters/Ratios (Pro-Forma2) Return On Capital Employed (RoCE) Return on Equity Asset / Turnover and Return On Asset (RoA) 1.8x 2.0x 20.2% 16.4% 9.4% (%age) 12.0% (%age) 6.6% FY20 FY21 FY21 FY20 FY21 ROCE % Return on Equity Asset / Turnover ROA % Net Working Capital Operating C

  27. Slide 27: Our Vision, Values, Promise and Philosophy

    Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing

  28. Slide 28: Thank you

    Thank you

  29. Slide 29: Thank you for your time

    For More Information For Investors: Siddharth Rangnekar CDR India Pavleen Taneja Ph: +91 22 6645 1209 Ph: +91 120 436 1021 E-mail: siddharth@cdr-india.com E-mail: pavleen.taneja@jubl.com For Media: Clayton Dsouza Sudhakar Safaya Madison Public Relations Ph: +91 120 436 1034 E-mail: clayton.dsouza@ma

  30. Slide 30: Appendix

    Appendix

  31. Slide 31: Pro-Forma Income Statement Consolidated – FY21

    Pro-Forma Income Statement Consolidated – FY21 (10 months discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months Jubilant Ingrevia Limited ) 10M'FY21 2M'FY21 Particulars1 FY20 FY21 YoY (%) Apr'20 to Jan'21 Feb'21 to Mar'21 Revenue from operations a) Sales/Income from operati

Jubilant Ingrevia — Investor Presentation (September 2021) on 6ix